A Comparison Study of Apadenoson and Adenosine to Treadmill Exercise Stress.
NCT00380198 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1500
Last updated 2017-02-01
Summary
The purpose of this clinical research study is to compare Apadenoson and adenosine to treadmill exercise stress SPECT MPI
Conditions
Interventions
- DRUG
-
Apadenoson
Sponsors & Collaborators
-
Forest Laboratories
lead INDUSTRY
Principal Investigators
-
Robert Mittleman, MD · Bristol-Myers Squibb
Study Design
- Allocation
- RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- DOUBLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2006-07-31
- Primary Completion
- 2006-11-30
- Completion
- 2006-11-30
Countries
- United States
Study Locations
More Related Trials
-
Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView.
NCT01936649 ·Status: COMPLETED ·Phase: PHASE4
-
Ticagrelor and Adenosine
NCT01996735 ·Status: COMPLETED ·Phase: PHASE4
-
Adenosin to Rapidly Reverse Left Ventricle Impairment in Takotsubo Syndrome
NCT02867878 ·Status: TERMINATED ·Phase: PHASE2
-
Regadenoson Combined With Symptom-Limited Exercise in Patients Undergoing Myocardial Perfusion Imaging
NCT01021618 ·Status: COMPLETED ·Phase: NA
-
Adenosine Cardioplegia; Improved Cardioprotection?
NCT01123525 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.
NCT03137537 ·Status: TERMINATED ·Phase: PHASE2
-
Eplerenone and Extracellular Adenosine Formation
NCT01837108 ·Status: COMPLETED ·Phase: PHASE4
-
BROKEN-SWEDEHEART- Optimized Pharmacological Treatment for Broken Heart (Takotsubo) Syndrome.
NCT04666454 ·Status: RECRUITING ·Phase: PHASE4
-
The Effects of Ambrisentan on Exercise Capacity in Fontan Patients
NCT01971580 ·Status: COMPLETED ·Phase: PHASE4
-
The Impact of the Routine Aminophylline Administration Following Regadenoson Stress on SPECT Myocardial Perfusion
NCT01655524 ·Status: WITHDRAWN ·Phase: PHASE4
-
Safety and Accuracy of Regadenoson-Atropine Stress Echocardiography in CAD
NCT00894179 ·Status: TERMINATED ·Phase: NA
-
A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction
NCT05139615 ·Status: TERMINATED ·Phase: PHASE2
-
Amiodarone and N-Acetylcysteine or Amiodarone Alone for Preventing Atrial Fibrillation After Thoracic Surgery
NCT02750319 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL180
NCT00907998 ·Status: COMPLETED ·Phase: PHASE1
-
Intravenous Allopurinol to Improve Heart Function in Individuals With Dilated Cardiomyopathy
NCT00281255 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction
NCT02053493 ·Status: COMPLETED ·Phase: PHASE2
-
Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction
NCT04912518 ·Status: RECRUITING ·Phase: NA
-
Inhibition of Aldosterone to Reduce Myocardial Diffuse Fibrosis in Patients With Paroxysmal and Persistent Atrial Fibrillation in Preventing Recurrent Episodes of Atrial Fibrillation
NCT02764619 ·Status: UNKNOWN ·Phase: PHASE3
-
Development of 1-Day Rest/Stress Cardiac PET Perfusion Imaging Protocol of BMS747158
NCT00849108 ·Status: COMPLETED ·Phase: PHASE2
-
Matching Perfusion and Metabolic Activity in HFpEF
NCT04913805 ·Status: RECRUITING ·Phase: PHASE2
-
Regadenoson and Adenosine
NCT01809743 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Rapamycin to Improve Cardiac Function in Frail Older Adults
NCT04996719 ·Status: COMPLETED ·Phase: PHASE1
-
Angiotensin Receptor Blockers in Aortic Stenosis
NCT04913870 ·Status: RECRUITING ·Phase: PHASE4
-
Circulating Adenosine Levels Before and After Intravenous (IV) Persantine
NCT00760708 ·Status: TERMINATED
-
Safety Study of Adenovirus Hepatocyte Growth Factor to Treat Ischemic Heart Disease
NCT01925352 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2